Corifollitropin Alfa Compared to Daily Recombinant FSH in in Vitro Fertilization Programmes: A Meta-Analysis of Randomized-Controlled Trials

Background: Corifollitropin alfa (CFA) is a long-acting recombinant follicle-stimulating hormone (rFSH) used for controlled ovarian stimulation (COS). Several studies analyzing the clinical efficacy and safety of CFA compared to daily rFSH during COS have been carried out. The present study offers meta-analysis randomized trials (RCTs) on this topic. Methods: A computerized search published literature was out using PubMed, MEDLINE, Science direct Google Scholar databases. comparison between treatments were investigated only in RCTs. primary endpoint represented by number total oocytes retrieved at ovum pick-up. included analysis pooled together order estimate log odds ratio (OR) or mean difference (MD) along with corresponding 95% confidence intervals (CI) random effects model. heterogeneity evaluated Higgins Chi-square tests. Results: examined twelve RCTs from 2004 date 4980 patients, 2664 receiving 2316 patients COS. Women treated had higher pick-up (MD 0.91, CI [0.34, 1.49], p = 0.001), metaphase II (MII) 1.00, [0.37, 1.62], 0.002) those rFSH. There no significant differences two groups regarding other outcomes analyzed. subgroup performed comparing “normal” versus “poor” responders revealed that normal showed an cancellation rate, respect Conclusions: This shows results